Archive 2015

2015

- 11 Nov 2015 – Press Release: Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphyloccocal Infections
- 22 Oct 2015 – G7 Health Minsters committed to tackle antimicrobial resistance
- 06 Oct 2015 – BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance release first position paper identifying the key actions required to reinvigorate investment and R&D in the antibacterial field
- 24 Aug 2015 – Latest figures from Public Health England show that the number of Methicillin Sensitive Staphylococcus aureus (MSSA) blood infection (bacteraemia) cases continue to rise in the UK
- 23 Jun 2015 – Destiny Pharma participates in the launch of the Antibiotic Discovery Global Network
- Destiny Pharma to attend the Society for Healthcare Epidemiology of America (SHEA) Spring 2015 Conference: Science Guiding Prevention in Orlando, Florida
- Destiny Pharma invited to present at the inaugural Pipeline Corner event to be held during the 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting in Copenhagen, Denmark on the 25-28th April 2015
- 05 Feb 2015 – Global Innovation Fund recommended to be set up to support new ideas to combat antimicrobial resistance
- 08 Jan 2015 – Destiny Pharma to attend DRIVE-AB (Driving reinvestment in R&D and the responsible use of antibiotics) meeting in London on February 9th